Momenimovahed Zohre, Mazidimoradi Afrooz, Allahqoli Leila, Khalajinia Zohre, Salehiniya Hamid, Alkatout Ibrahim
Reproductive Health Department, Qom University of Medical Sciences, Qom 3715835155, Iran.
Epidemiology Department, Shiraz University of Medical Sciences, Shiraz 7134845794, Iran.
Explor Target Antitumor Ther. 2025 May 15;6:1002316. doi: 10.37349/etat.2025.1002316. eCollection 2025.
Different tumor markers are utilized in the assessment of breast cancer. The function of these markers in assessing, tracking, and following up on breast cancer has drawn the interest of numerous researchers. Nonetheless, contradictory findings from research continue to raise questions regarding their effectiveness. Consequently, this research was carried out to evaluate the efficacy of carbohydrate antigen-125 (CA-125) in the treatment of breast cancer.
A thorough investigation was performed in the PubMed, Scopus, and Web of Science databases utilizing relevant keywords: CA-125, breast cancer, screening and diagnosis, and Mesh to locate articles published before August 2023 without any time limitations. The analysis included observational studies in English pertinent to the study's objective, while review articles, case reports, editor letters, comments, and other reports were not considered. Articles were sought, examined, included, and evaluated according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses. The EndNote X9 program has been utilized for item management. The review included articles that investigated the predictive function of CA-125 in the screening, diagnosis, and anticipation for the early and proper detection of breast cancer.
In the initial search, 1,475 articles were obtained. After screening and eligibility assessment, 33 studies were reviewed. Based on the findings of the studies, CA-125 can play a role in the diagnosis of breast cancer, its type and stage, early detection of recurrence and metastasis, treatment efficiency, prognosis, and survival rate.
The role of CA-125 as a biomarker for early detection, staging, and monitoring of recurrence and metastasis in breast cancer is still uncertain and needs additional research.
不同的肿瘤标志物被用于乳腺癌的评估。这些标志物在评估、追踪和随访乳腺癌方面的作用引起了众多研究人员的兴趣。尽管如此，研究中相互矛盾的结果仍不断引发关于其有效性的质疑。因此，本研究旨在评估糖类抗原125（CA - 125）在乳腺癌治疗中的疗效。
在PubMed、Scopus和Web of Science数据库中进行了全面检索，使用相关关键词：CA - 125、乳腺癌、筛查与诊断以及Mesh，以查找2023年8月之前发表的文章，无时间限制。分析纳入了与研究目的相关的英文观察性研究，而综述文章、病例报告、编辑信件、评论及其他报告均未纳入。根据系统评价和Meta分析的首选报告项目指南查找、审查、纳入并评估文章。使用EndNote X9程序进行项目管理。该综述纳入了研究CA - 125在乳腺癌筛查、诊断以及早期和准确检测预测功能的文章。
在初步检索中，共获得1475篇文章。经过筛选和资格评估，对33项研究进行了综述。根据研究结果，CA - 125可在乳腺癌的诊断、类型和分期、复发和转移的早期检测、治疗效果、预后及生存率方面发挥作用。
CA - 125作为乳腺癌早期检测、分期以及复发和转移监测生物标志物的作用仍不确定，需要进一步研究。
